Pioneering defense against emerging biological threats

Emerging infectious diseases represent one of the greatest threats to global health. Disease X — a placeholder for the next unknown pandemic pathogen — may arise as a novel zoonotic virus, bacterium, fungus, or parasite, or as a mutated strain of an existing pathogen capable of evading current diagnostics, treatments, and vaccines.

Nucalix has pioneered TerX™, a technology with the unprecedented ability to neutralize a wide range of pathogens — including those not previously encountered. Rather than targeting a single known pathogen, TerX™ operates on conserved biological mechanisms shared across pathogen families, enabling broad-spectrum efficacy.

We use high-throughput sequencing and screening techniques to rapidly identify the most potent drug candidates. Machine learning and bioinformatics then optimize each candidate for potency, specificity, and safety — compressing a process that historically took years into weeks.

TerX™ generates therapeutics for immediate treatment, vaccines for long-term prevention, and rapid diagnostics — enabling a complete response to emerging threats from a single integrated pipeline.